Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Abstract
Objective
Methods
Results
Conclusions
Get full access to this article
View all available purchase options and get full access to this article.
References
Information & Authors
Information
Published In
Copyright
Publication History
Disclosure
Study Funding
Authors
Author Contributions
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases, Journal of Neurology, 272, 2, (2025).https://doi.org/10.1007/s00415-025-12910-x
- Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials, Brain, 147, 10, (3513-3521), (2024).https://doi.org/10.1093/brain/awae216
- Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy, The Lancet Neurology, 23, 10, (1025-1034), (2024).https://doi.org/10.1016/S1474-4422(24)00335-1
- Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs, Neurology, 100, 20, (e2114-e2124), (2023)./doi/10.1212/WNL.0000000000207156
- Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics, Brain, 146, 11, (4414-4424), (2023).https://doi.org/10.1093/brain/awad188
- Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease, Nature Communications, 14, 1, (2023).https://doi.org/10.1038/s41467-023-43933-5
- Passive Alzheimer’s immunotherapy: A promising or uncertain option?, Ageing Research Reviews, 90, (101996), (2023).https://doi.org/10.1016/j.arr.2023.101996
- Medicine-Food Herbs against Alzheimer’s Disease: A Review of Their Traditional Functional Features, Substance Basis, Clinical Practices and Mechanisms of Action, Molecules, 27, 3, (901), (2022).https://doi.org/10.3390/molecules27030901
- Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?, International Journal of Molecular Sciences, 23, 4, (2011), (2022).https://doi.org/10.3390/ijms23042011
- Associations of Naturally Occurring Antibodies to Presenilin-1 with Brain Amyloid-β Load and Cognitive Impairment in Alzheimer’s Disease, Journal of Alzheimer's Disease, 90, 4, (1493-1500), (2022).https://doi.org/10.3233/JAD-220775
- See more
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.